中欧领导人会晤是否将于下周举行？外交部回应 据环球网，在17日的外交部例行记者会上，有媒体提问称，外交部能否确认中欧领导人会晤是否将于下周举行，并提供相关细节？ 外交部发言人林剑7月17日主持例行记者会。 对此，外交部发言人林剑表示，目前我没有可以提供的信息。 中俄印正就恢复三方合作机制谈判？外交部回应 有媒体提问称，俄罗斯外交部副部长鲁登科正与中国和印度就恢复三方合作机制进行谈判，他称俄罗斯对推动该机制的运作保持积极态度，请问中方对此有 何评论？ 对此，林剑表示，中俄印合作不仅符合三国的自身利益，也有利于地区乃至全球和平安全稳定与进步。中方愿同俄印双方就推进中俄印合作保持沟通。 外交部：芬太尼是美国的问题，不是中国的问题，责任在美国自身 据媒体报道，美国总统特朗普16日称，他认为中国很快会对制造和分销毒品芬太尼的人员判处死刑，他对与北京就非法毒品问题达成协议的前景感到乐观。 对此，林剑17日在外交部例行记者会上回应相关问询时表示，我们多次表明，芬太尼是美国的问题，不是中国的问题，责任在美国自身。美方无视中方的善 意，执意对中国加征芬太尼关税，这严重冲击中美在禁毒领域的对话与合作，也严重损害中方利益。美国如果 ...

Core Viewpoint - The Chinese Foreign Ministry emphasizes that fentanyl is an issue for the United States, not China, and criticizes the U.S. for imposing tariffs on Chinese fentanyl, which disrupts dialogue and cooperation in drug control between the two countries [1] Group 1 - The Chinese government has repeatedly stated that the responsibility for fentanyl issues lies with the U.S. itself [1] - The U.S. has ignored China's goodwill and insisted on imposing tariffs on fentanyl, which severely impacts bilateral dialogue and cooperation in drug control [1] - The Chinese Foreign Ministry calls for the U.S. to engage in dialogue with China in a manner that is equal, respectful, and mutually beneficial [1]

Group 1 - The core point of the news is the recent US-China trade negotiations, which resulted in a temporary suspension of tariffs and a reduction of certain tariffs, signaling a potential easing of trade tensions between the two countries [1][17] - The negotiations progressed faster than expected, with the US agreeing to only a 10% base tariff instead of the previously proposed 145% [1][4] - The US's approach to the negotiations reflects a sense of urgency from the Trump administration, as they seek to find a way to ease trade tensions without incurring further economic damage [2][5] Group 2 - The current trade situation is characterized by a significant imbalance, with the US imposing additional tariffs on China under the pretext of issues like fentanyl, which complicates the negotiation landscape [4][5] - The upcoming 90-day suspension period is seen as a critical window for China to leverage the US's impending debt crisis as a bargaining chip in future negotiations [10][11] - China's strategy in the negotiations is to maintain a strong position, recognizing that the trade war has impacted the US more significantly than it has affected China [5][17] Group 3 - The historical context of the negotiations indicates that previous experiences with the Trump administration have equipped China with better strategies to handle potential future confrontations [13][14] - The reliance of the US on Chinese supply chains, particularly in areas like rare earth materials, gives China leverage in the negotiations [14] - The overall sentiment is that while the recent negotiations represent a temporary victory for China, there remains a high level of uncertainty regarding future interactions with the Trump administration [9][17]

中美在日内瓦达成联合声明，过去几年积压的关税摩擦被按下"暂停键"——91%的对华加征关税直接取消，其余则暂缓执行，市场一片欢腾：股市飙涨、黄 金跳水、美元升值……这一切都释放出一个信号：中美关系或正迈向"破冰时刻"。采取上述举措后，双方将建立机制，继续就经贸关系进行协商。协商可在 中国、美国，或双方商定的第三国进行。根据需要，双方可就相关经贸议题开展工作层面磋商。 据北京商报报道，彭博社记者：美国前驻华大使伯恩斯称，美方已向中方明确表示，如不能协调解决芬太尼问题，中方将付出代价；中方确有能力阻止易制 毒化学品流动。外交部对此有何回应？发言人表示：我刚才已经表明了中方在芬太尼关税问题上的原则立场。此前我们也多次表明，芬太尼是美国的问题， 不是中国的问题，责任在美国自身。美方无视中方善意，对中国无理加征芬太尼关税，这严重冲击中美在禁毒领域的对话与合作，也严重损害中方利益。美 方如果真心想同中方合作，就应该停止对华抹黑推责，以平等、尊重、互惠的方式同中方进行对话 特朗普（资料图） 此轮关税风波凸显政策稳定性对全球供应链的关键意义，也为中美"合则两利、斗则俱伤"的结论增添了最新注脚。 从中国出发跨越太平洋的货船，承载 ...

大宗商品研究所 能化研发报告 玻璃期货日报 2025 年 5 月 14 日 玻璃期货日报 第一部分 基础数据 | 现货市场（元/吨） | 2025/5/13 | 2025/5/12 | 上周 | 日变化 | 周变化 | | --- | --- | --- | --- | --- | --- | | 沙河长城 | 1181 | 1181 | 1198 | 0 | -17 | | 沙河安全 | 1220 | 1220 | 1228 | 0 | -9 | | 沙河德金 | 1164 | 1164 | 1173 | 0 | -9 | | 沙河大板 | 1190 | 1194 | 1207 | -4 | -17 | | 湖北大板 | 1120 | 1160 | 1160 | -40 | -40 | | 浙江大板 | 1400 | 1400 | 1400 | 0 | 0 | | 华南大板 | 1320 | 1320 | 1320 | 0 | 0 | | 东北大板 | 1240 | 1240 | 1240 | 0 | 0 | | 西北大板 | 1280 | 1280 | 1280 | 0 | 0 | | 西南大板 | 13 ...

Group 1 - The core viewpoint of the article emphasizes the importance of equal and respectful dialogue between China and the United States, particularly regarding trade negotiations and the fentanyl issue [2][3] - The Chinese government has reiterated that fentanyl is primarily a problem for the United States, and the imposition of tariffs by the U.S. on China regarding this issue is seen as detrimental to bilateral cooperation in drug control [2] - The China-Latin America Forum is highlighted as a significant platform for mutual cooperation between China and Latin American countries, with China expressing support for participation from member states [4] Group 2 - The second phase of the Artificial Intelligence Capacity Building Seminar was launched in Beijing, with participation from nearly 40 countries and international organizations, aimed at promoting international cooperation in AI capacity building [5] - The Chinese government advocates for AI to be a public good that benefits humanity, emphasizing the need for equitable development and sharing of digital dividends among developing countries [5] - China aims to strengthen international collaboration in AI and is committed to providing public goods to the international community, ensuring that the benefits of the AI revolution are shared widely [5]

Group 1 - The core point of the news is the significant concessions made by the U.S. in the recent U.S.-China tariff negotiations, resulting in a joint statement that exceeded expectations [2][3] - Both the U.S. and China agreed to cancel a cumulative 91% of tariffs imposed on each other's goods, marking a substantial reduction in trade barriers [3][4] - Additionally, both countries will suspend another 24% of tariffs for a period of 90 days, indicating a temporary easing of trade tensions [4][16] Group 2 - The U.S. decision to compromise is attributed to several factors, including domestic pressure from rising prices and declining public support for Trump's policies [6][9] - The U.S. has found that its high tariffs on China are not yielding the intended results, as China's manufacturing capabilities remain unmatched globally [9][11] - The ongoing geopolitical situation, including conflicts involving Pakistan and India, has also influenced the U.S. to seek a temporary resolution with China [12][20] Group 3 - Despite the concessions, the U.S. has not removed the additional 20% tariffs related to the fentanyl issue, indicating an ongoing imbalance in tariff rates between the two countries [14][15] - The 90-day suspension of the 24% tariffs introduces uncertainty, as these tariffs could be reinstated depending on future developments in U.S.-China relations or supply chain alternatives [16][18] - The overall conclusion is that the recent tariff negotiations signify a new starting point in U.S.-China relations, with ongoing challenges expected in the future [20]

Core Viewpoint - The Chinese government expresses strong dissatisfaction and firm opposition to the U.S. threat of imposing an additional 10% tariff on Chinese products, citing the fentanyl issue as the reason [1]. Group 1 - The U.S. plans to impose tariffs starting March 4, using the fentanyl crisis as a pretext, which China views as an unjustified action [1]. - China emphasizes its strict drug control policies and international cooperation efforts in combating drug issues, asserting that it has made significant contributions to addressing the fentanyl problem [1]. - The root cause of the fentanyl crisis is identified as domestic issues within the U.S., and China urges the U.S. to focus on reducing domestic drug demand and enhancing law enforcement cooperation [1]. Group 2 - The Chinese government warns that the U.S. approach of shifting blame to other countries will not resolve the underlying issues and could severely impact Sino-U.S. cooperation in drug control [1]. - China calls for the U.S. to correct its erroneous actions and to maintain the positive momentum of bilateral drug control cooperation, which has been hard-won [1].

美国特朗普政府近期宣布的关税政策引发了 全球多国的强烈反应 ，并对各个行业，尤其是医疗行业，产生了深远的影响。以下是思宇MedTech梳理的最新进 展以及分析。注意，事态一直在变化，这是截止2025年2月5日的情况。 思宇备注：医疗器械市场准入门槛高以及美国食品药品监督管理局（FDA）严格的审批要求，企业在调整生产布局、变更工厂所在地时面临诸多障碍。生产线的迁 移不仅需要经过繁琐的审批流程，还必须确保新厂房的产品符合FDA的所有质量和安全标准，这一过程往往需要耗费数月甚至数年的时间。 对于那些依赖现有海外供应链的公司来说，短期内实现生产基地的转移既不现实，也极为不便。 1. 关税延期执行： 特朗普原定于2月4日生效的对加拿大、墨西哥的25%关税和对中国10%关税，经过谈判后做出调整： 2. 各国反制措施： 关税对医疗行业的影响 1. 供应链挑战： 2. 美国的医疗产品成本攀升： 3. 跨国医疗企业连带风险： 除了美国公司， "墨西哥制造"的中国企业也受到冲击： 中资企业在墨西哥（如北美华富山工业园）面临双重压力，包括可能恢复的25%关税，以及美国要求 墨西哥限制中国"借道出口"的措施。 供应链追溯要求： 美国 ...